Recent Updates
Recently added Catalysts
MBX Positive Sentiment Score: 70/100

MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Tuesday, March 7, 2023 1 min read
Key Takeaway: MBX Biosciences, a clinical stage biopharmaceutical company, is set to present at the Oppenheimer 33rd Annual Healthcare Conference. The event will occur virtually on March 14, 2023, with CEO Kent Hawryluk leading the presentation. This participation signifies MBX's active engagement in the healthcare sector and offers an opportunity to showcase their Precision Endocrine Peptide™ therapeutics. Such events are crucial for networking and gaining investor interest in the company's endeavors.

Market Sentiment Analysis

POSITIVE FACTORS

  • MBX Biosciences is actively participating in a significant healthcare conference.
  • The presentation could enhance visibility for MBX's innovative therapies.
  • Kent Hawryluk's involvement highlights the leadership's commitment to share advancements.

Full Press Release Details

CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced its participation at the virtual Oppenheimer 33rd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Tuesday, March 14, 2023 at 10:40 a.m. ET.
About MBX Biosciences
ian.stone@evokegroup.com
robert.uhl@westwicke.com

Tags

Frequently Asked Questions

What is MBX Biosciences known for?

MBX Biosciences is focused on developing Precision Endocrine Peptide™ therapeutics for endocrine disorders.

When will MBX Biosciences present at the conference?

MBX Biosciences will present on Tuesday, March 14, 2023, at 10:40 a.m. ET.

Who is the CEO of MBX Biosciences?

Kent Hawryluk is the President and Chief Executive Officer of MBX Biosciences.

What is the nature of MBX Biosciences?

MBX Biosciences is a clinical stage biopharmaceutical company.

Tags: MBX Viatris Investor Conferences Healthcare healthcare conference biopharmaceutical Kent Hawryluk endocrine disorders
Last updated: Mar 7, 2023